Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06651632

WATER IV Prostate Cancer

This is a multicenter, prospective, randomized clinical trial that aims to assess the safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, prostatectomy. Participants will be randomized to either Aquablation Therapy or radical prostatectomy and followed up to 10 years.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

45 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Toronto, Toronto, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biological male with age ≥ 45 years at the time of consent
  • Biopsy positive Grade Group 1-3 prostate cancer
  • Are candidates for prostatectomy or, in the case of GG1 disease, have already selected a radical therapy as their treatment.
  • Clinical Stage ≤ T2c
  • PSA ≤ 20 ng/ml
  • Prostate volume ≥25 ml

Exclusion criteria

  • Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
  • Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
  • Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
  • Patient is unwilling to accept a blood transfusion if required.
  • Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:

5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).

  • Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.
  • Patient currently participating in other studies unless approved by Sponsor in writing.

Treatment and study plan

Aquablation Therapy

Device

The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.

radical prostatectomy

Procedure

Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.

Primary outcomes

  1. Rate of pad use for urinary incontinence

    Time frame: 6 Months

  2. Rate of erectile dysfunction

    Time frame: 6 Months

Secondary outcomes

  1. Rate of pad use for urinary incontinence

    Time frame: 3 Months

  2. Rate of erectile dysfunction

    Time frame: 3 Months

  3. Stable or improved Grade Group at 1 year compared to baseline (Aquablation arm only)

    Time frame: 1 Year

Sponsors and collaborators

Lead sponsor

PROCEPT BioRobotics

Industry

Registry information

Official study title

WATER IV Prostate Cancer: Aquablation Versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer

Acronym: WATER IV PCa

Important dates

Study start
2025
Primary completion
2027
Study completion
2037
First posted
Oct 22, 2024
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.